Abstract
The authors assessed the prevalence of headaches following extended-release dipyridamole/aspirin combination (DAC), and the efficacy of acetaminophen in the treatment of these headaches. Following DAC, 38.7% of the participants developed headaches. The headaches were self-limited (69.4% placebo efficacy in 2 hours) and the incidence markedly declined over time. Acetaminophen was no more effective than placebo in the acute and preemptive treatment of these headaches.
Original language | English (US) |
---|---|
Pages (from-to) | 1099-1101 |
Number of pages | 3 |
Journal | Neurology |
Volume | 63 |
Issue number | 6 |
DOIs | |
State | Published - Sep 29 2004 |
ASJC Scopus subject areas
- Clinical Neurology